ArticlePharmacoEconomics - open2026
Assessing the Expected Costs of Continuous Remote Monitoring for Post-Discharge Home Use and the Readmission Reduction Required to Achieve Cost Neutrality.
Article in PharmacoEconomics - open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectiveHospital-level care at home is gaining traction, but evidence on health economic implications remains limited. The aim of this study was to estimate expected costs of continuous remote monitoring of vital signs in the post-discharge setting, to assess the burden of readmissions among relevant patient groups, and to compare monitoring costs with the potential savings from reduced readmissions. The study was conducted from a restricted societal perspective within the Danish healthcare system.
methodsThe costs of 3-day post-discharge home monitoring were estimated using a micro-costing approach based on the WARD-Home project. The analysis excluded healthcare costs incurred outside the hospital sector or beyond the 3-day period. Readmission rates, length of stay, and associated costs were analyzed using Danish registry data on patients potentially suitable for post-discharge monitoring but currently not receiving it.
resultsEstimated per-patient costs of 3-day monitoring were EUR 159. Registry data showed an overall 3-day readmission rate of 1.7%, with average length of stay of 4.4 days, and costs of EUR 4674. Comparing average costs of readmissions within 3 days-corresponding to monitoring duration-with the monitoring costs indicated that if post-discharge monitoring reduces readmissions, cost-neutrality could be achieved if it prevents one readmission in every 29 patients monitored.
conclusionsContinuous remote monitoring offers a solution to post-discharge patients at risk of short-term deterioration and readmission. If one readmission is prevented per every 29 patients monitored, the approach has the potential to achieve cost-neutrality. Future studies are needed to validate these estimates and determine whether reductions in readmissions and actual cost savings can be achieved in practice.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.